2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Any Solid Tumor: new trials by email Literature Review of Any Solid Tumor trials Research Report on Any Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations LY3410738, Gemcitabine, Cisplatin - Cholangiocarcinoma, Chondrosarcoma | Phase 1 | Active not recruiting | Eli Lilly and Company | 200 | 2020-10-01 | 2026-07-22 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
Breast Neoplasms (2) · Central Nervous System Neoplasms (2) · Colonic Neoplasms (2) · Thyroid Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Chondrosarcoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1)
Adenocarcinoma (2) · Breast Diseases (2) · Carcinoma (2) · Colonic Diseases (2) · Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2)
Cisplatin (1) · Gemcitabine (1) · durvalumab (1) · selpercatinib (1)
Australia (2) · France (2) · Hong Kong (2) · Japan (2) · Singapore (2) · South Korea (2) · Spain (2) · Taiwan (2) · United States (2) · Canada (1) · Denmark (1) · Germany (1) · Israel (1) · Italy (1) · Switzerland (1)
PMID 32846060, PMID 32846061, PMID 34088726, PMID 35930972, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37934000, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39983053
2017 (1), 2023 (1)